Benitec Biopharma Inc.
BNTCNasdaq
$12.78
↑ +0.9%Jul 17 close · end-of-day
Price
1Y↑ +8.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$631.2M
Enterprise Value
$446.4M
P/E
—
P/S
—
P/B
3.4
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$41.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-22.7%
ROIC
—
Debt / Equity
—
Net Cash
$184.8M
Return 1Y
+8.9%
Company profile
Benitec Biopharma focuses on the development of novel genetic medicines. The company is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. BB-103 for the treatment of chronic hepatitis B virus infection.
- CEO
- Jerel A. Banks
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- California
- Website
- benitec.com
Earnings
BNTC Q3 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00—
Diluted EPS-$0.24↓ -36.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $59,000.00 | $73,000.00 | $75,000.00 | $0.00 | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$13.6M | -$17.9M | -$19.1M | -$22.5M | -$41.8M |
| Net income | -$13.9M | -$18.2M | -$19.6M | -$21.8M | -$37.9M |
| Diluted EPS | -$3.23 | -$37.88 | -$14.12 | -$1.22 | -$1.05 |
| Operating cash flow | -$12.8M | -$15.9M | -$18.0M | -$19.4M | -$23.6M |
| Free cash flow | -$13.1M | -$15.9M | -$18.0M | -$19.6M | -$23.6M |
| Gross margin | — | — | — | — | — |
| Operating margin | -23044.1% | -24457.5% | -25441.3% | — | — |
| Net margin | -23528.8% | -24942.5% | -26082.7% | — | — |
| Line item | Q4 '24 | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.5M | -$5.8M | -$10.8M | -$15.3M | -$9.8M | -$9.8M | -$13.4M | -$13.6M |
| Net income | -$4.7M | -$5.1M | -$9.6M | -$14.5M | -$8.8M | -$9.0M | -$11.8M | -$11.9M |
| Diluted EPS | $4.70 | -$0.18 | -$0.26 | -$0.38 | -$0.21 | -$0.22 | -$0.26 | -$0.24 |
| Operating cash flow | -$3.3M | -$4.6M | -$7.7M | -$3.1M | -$8.2M | -$3.4M | -$3.8M | -$4.5M |
| Free cash flow | — | — | — | -$3.1M | — | — | — | -$4.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
Latest 15 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.